Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
1999-05-28
2003-04-08
Mosher, Mary E. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007930, C435S007940, C436S064000
Reexamination Certificate
active
06544749
ABSTRACT:
FIELD OF THE INVENTION
This application relates to hybrid cell lines (lymphocyte hybridomas) for the production of monoclonal antibodies to human leukemia inhibitory factor, to such homogeneous monospecific antibodies, and to the use of such antibodies for diagnostic and therapeutic purposes.
BACKGROUND OF THE INVENTION
Leukemia inhibitory factor (LIF) is a polypeptide with a broad range of biological effects. LIF was initially purified from mouse cells and identified on the basis of its ability to induce differentiation in and suppress the proliferation of the murine monocytic leukemia cell line M1. Tomida, et al., J. Biol. Chem. 259:10978-10982 (1984); Tomida, et al., FEBS Lett. 178:291-296 (1984). Human LIF (hLIF) subsequently was shown to have comparable effects on human HL60 and U937 cells, particularly when acting in collaboration with GM-CSF or G-CSF colony stimulating factors. Maekawa, et al. Leukemia 3:270-276 (1989).
LIF has been shown to exhibit a variety of biological activities and effects on different cell types. For example, it has been shown to stimulate osteoblast proliferation and new bone formation, Metcalf, et al., Proc. Nat. Acad. Sci., 86:5948-5952 (1989), as well as bone resorption, Abe, et al., Proc. Nat. Acad. Sci. 83:5958-5962 (1986); Reid, et al., Endocrinology 126:1416-1420 (1990), stimulate liver cells to produce acute phase plasma proteins, Baumann, et al., J. Immunol. 143:1163-1167 (1989), inhibit lipoprotein lipase, Mori, et al., Biochem. Biophys. Res. Commun. 160:1085-1092 (1989), stimulate neuronal differentiation and survival, Murphy, et al., Proc. Nat. Acad. Sci. 88:349-3501 (1991), Yamamori, et al., Science 246:1412-1416 (1989), and inhibit vascular endothelial cell growth, Ferrara, et al., Proc. Nat. Acad. Sci. 89:698-702 (1992). Receptors for LIF have been found on monocyte-macrophages, osteoblasts, placental trophoblasts, and liver parenchymal cells. Hilton, et al., J. Cell. Biochem. 46:21-26 (1991); Allan, et al., J. Cell. Physiol. 145:110-119 (1990); Hilton, et al., Proc. Nat. Acad. Sci. 85:5971-5975 (1988).
Depending upon its particular activity or effect, LIF has been referred to by various names, including differentiation-inducing factor (DIF, D-factor), hepatocyte-stimulating factor (HSF-II, HSF-III), melanoma-derived LPL inhibitor (MLPLI), and cholinergic neuronal differentiation factor (CDP). Hilton, et al., J. Cell. Biochem. 46:21-26 (1991).
Genomic and CDNA clones encoding murine, rat, and human LIF have been isolated. Gearing, et al., EMBO J. 6:3995-4002 (1987); Yamamori, et al., Science 246:1412-1416 (1989); Gough, et al., Proc. Nat. Acad. Sci. 85:2623-2627 (1988).
Antibodies to hLIF are expected to have valuable diagnostic and therapeutic applications, such as in assaying for the presence of hLIF in clinical specimens, and in regulating the biological effects of hLIF and the interaction of hLIF with its receptors and other ligands. In particular, monoclonal antibodies (mAbs) detecting unique epitopes of hLIF would be of great value in understanding and regulating the diverse biological activities of hLIF. Neutralizing mAbs specific for hLIF that inhibit one or more of the biological activities or effects of hLIF have great potential as therapeutic agents useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone resorption (such as may be associated with osteoporosis).
Several polyclonal antibodies have been described that react with LIF. Tomida, et al., FEBS Letters 151:281-285 (1983) immmunized rabbits with partially purified D-factor from mouse cells, and obtained antibodies capable of neutralizing the activity of mouse D-factor, and to a lesser extent, rat and hamster D-factors, in several assays. Baumann, et al., J. Immunol. 143:1163-1167 (1989) reported that rabbit polyclonal antibodies against hepatocyte-stimulating factor III (HSF-III) neutralized the activity of hLIF on hepatic cells.
There is a need for high affinity monoclonal antibodies to hLIF that are capable of effective inhibition of the biological activities of hLIF. It would be particularly desirable to provide monoclonal antibodies that are effective inhibitors of hLIF binding to its receptors, but which do not interfere with the binding of other factors, such as interleukin 1 (IL-1), interleukin 3 (IL-3), interleukin 6 (IL-6), tumor necrosis factor-&agr; (TNF-&agr;), granulocyte CSP (G-CSF), granulocyte-macrophage-colony stimulating factor (GM-CSF), and Oncostatin M.
SUMMARY OF THE INVENTION
The present invention is based on successful research involving the production and extensive characterization of monoclonal antibodies to hLIF. Accordingly, the present invention is directed to monoclonal antibodies, and derivatives thereof, which are capable of recognizing unique epitopes on hLIF and/or which exhibit high affinity for hLIF. The invention is further directed to monoclonal antibodies capable of inhibiting one or more of the biological activities of hLIF.
In one aspect, the invention concerns an anti-hLIF monoclonal antibody that is capable of inhibiting the mitogenic effect of hLIF on leukemic cells, and that does not cross-react with IL-1, IL-3, IL-6, TNF-&agr;, G-CSF, or GM-CSF.
In another aspect, the invention concerns isolated nucleic acid encoding such antibodies, and hybridoma or recombinant cells producing such antibodies.
In a further aspect, the invention concerns the therapeutic or diagnostic use of such antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents, either by themselves or in conjunction with (chemo)therapeutic agents, to treat diseases or conditions that are aggravated by hLIF. The monoclonal antibodies of the invention also are useful in diagnostic and analytical assays for determining the presence of hLIF in clinical specimens.
These and further aspects will be apparent from the following detailed description.
REFERENCES:
patent: 4722899 (1988-02-01), Hamaoka et al.
patent: 5045451 (1991-09-01), Uhr et al.
patent: 5106951 (1992-04-01), Morgan, Jr. et al.
patent: 5654157 (1997-08-01), Kim
patent: WO 91/13985 (1991-09-01), None
Huston, J.S. et al. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli.Proc. Natl. Acad Sci. USA, 85:5879-5883, Aug. 1988.*
Goding, J.W. Monclonal Antibodies: Principles and Practice. Academic Press, Inc. London, pp. 118-123, 1983.*
Abe et al., “Differentiation-Inducing Factor Purified From Conditioned Medium of Mitogen-Treated Spleen Cell Cultures Stimulated Bone Resorption”Proc. Natl. Acad. Sci. USA83:5958-5962 (1986).
Allan et al., “Osteoblasts Display Receptors for and Responses to Leukemia-Inhibitory Factor”J. Cellular Physiology145:110-119 (1990).
AlphonsoJ. Leukocyte Biol.10:49 (1991).
Baumann et al., “Hepatocyte-Stimulating Factor III Shares Structural and Functional Identity with Leukemia-Inhibitory Factor”J. Immonul.143:1163-1167 (1989).
Borrebaeck, Carl A.K., “Strategy for the production of human monoclonal antibodies using in vitro activated B cells”J. Immunol. Methods123:157-165 (1989).
Davies, Tony, “Magic Bullets”Nature289:12-13 (1981).
DillmanAnnals of Internal Medicine111:594 (1989).
Ferrara et al., “Pituitary Follicular Cells Secrete and Inhibitor of Aortic Endothelial Cell Growth: Identification as Leukemia Inhibitory Factor”Proc. Natl. Acad. Sci. USA89:698-702 (1992).
Gearing et al., “Molecular Cloning and Expression of cDNA Encoding a Murine Myeloid Leukaemia Inhibitory Factor (LIF)”The EMBO Journal6(13) :3995-4002 (1987).
Gough et al., “Molecular Cloning and Expression of the Human Homologue of the Murine Gene Encoding Myeloid Leukemia-Inhibitory Factor”Proc. Natl. Acad. Sci. USA85:2623-2627 (1988).
Harris et al., “Therapeutic Antibodies—The Coming of Age”Tibtech11:42-44 (Feb. 1993).
Hilton et al., “Leukemia Inhibitory Factor: A Biological Perspective”J. Cell Biochem.46:21-26 (1991).
Hilton et al., “Specific Binding of Mu
Conley Deidre L.
Genentech Inc.
Mosher Mary E.
Yu Misook
LandOfFree
Antibodies to leukemia inhibitory factor and their use in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to leukemia inhibitory factor and their use in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to leukemia inhibitory factor and their use in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3025954